LYEL · CIK 0001806952 · FY2025 live · 2025-12-31
Lyell Immunopharma, Inc.
View as
Model
Classic Z
FY2025
−6.91
Zone
Distress
Prior
—
Market DD
—
1y PD
—
−6.91
Z″ −13.93
Score −6.91 · distress below 1.80, grey to 2.99, safe at 3.00 and above.
Classic Z factor contributions
X1 Working capital / assets
Short-term liquidity versus the size of the balance sheet.
0.621.2 × = 0.75X2 Retained earnings / assets
Cushion from years of profits. Share buybacks can push this negative at otherwise healthy firms.
−4.761.4 × = −6.67X3 EBIT / assets
Operating return on assets. Highest weight in the original model.
−0.793.3 × = −2.61X4 Book equity / liabilities
Book equity versus the liability stack. Mega-caps often look greyer here than they would if X4 used market cap.
2.700.6 × = 1.62X5 Sales / assets
Asset turnover — how much revenue the asset base supports.
0.001 × = 0.00
Five-year path
Need two annual 10-Ks to draw a path. The desk will pull this issuer’s filings rather than invent a series.
Overview
rule-v1
Lyell Immunopharma, Inc. is on classic Z at −6.91 (distress) for FY2025, from an SEC 10-K. Retained earnings / assets is the line that sets the print. This is the first live year on the desk. No market tape loaded. Classic Z was fit on manufacturers; buybacks can send retained earnings negative at otherwise healthy issuers, and X4 is book equity, not market cap.
Book screen Distress; market PD —. Tape not priced — not a single default call.
Market DD · naive Merton
No market tape yet.
Pull a year of closes (Yahoo, Nasdaq if Yahoo is limited) and size equity from Nasdaq cap or EDGAR shares. Distance-to-default and 1-year PD stay blank until then.
Sector peers
Closest Classic Z scores · 22nd percentile in Healthcare.
- FLNADistressFILANA THERAPEUTICS, INC.−6.97
- KRRODistressKorro Bio, Inc.−6.98
- VANIDistressVivani Medical, Inc.−6.84
- BBIODistressBridgeBio Pharma, Inc.−6.79
- SLNDistressSilence Therapeutics plc−6.77
- HYPDDistressHYPERION DEFI, INC.−7.06
- LRMRDistressLarimar Therapeutics, Inc.−6.75
- REPLDistressReplimune Group, Inc.−7.10
KPI widgets
Current assets
$261M
Total assets
$340M
Current liabilities
$49M
Total liabilities
$92M
Working capital
$212M
Retained earnings
−$1.6B
EBIT
−$269M
Total sales
$36K
Book equity
$248M
Accession 0001628280-26-017253. Live rank is the latest 10-K on EDGAR (FY2025, period 2025-12-31). Classic Z is the live score. View as does not rewrite the live rank. X4 is book equity. Pulled 12 Sept 2026.